Tarsus Pharmaceuticals (TARS) Change in Accured Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$9.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 57.05% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at $3.5 million (down 10.02% YoY), while the FY2025 annual figure was $6.9 million, up 171.46% from the prior year.
• Change in Accured Expenses was -$9.2 million for Q1 2026 at Tarsus Pharmaceuticals, down from $9.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $19.5 million in Q2 2025 to a low of -$15.9 million in Q3 2025.
• Historically, Change in Accured Expenses has averaged $572000.0 across 5 years, with a median of $975000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses soared 1063.39% in 2023, then tumbled 596.65% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$366000.0 in 2022, then jumped by 1063.39% to $3.5 million in 2023, then climbed by 26.6% to $4.5 million in 2024, then surged by 105.6% to $9.2 million in 2025, then plunged by 200.78% to -$9.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$9.2 million (Q1 2026), $9.2 million (Q4 2025), and -$15.9 million (Q3 2025), per Business Quant data.